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Summary Twenty-five patients with advanced solid tumours were entered in a phase I/II study of six, weekly
cycles of cisplatin. Nineteen patients were chemonaive and six were previously treated. The starting dose was
50 mgm-2 week-'. This dose could be escalated without major toxicity to 70 mg m-2 week-'. At a dose of
80 mg m-2 myelosuppression grade 3 occurred as well as grade I nephro- and neurotoxicity. The maximum
tolerated dose was 85 mg m-2 with dose limiting thrombocytopenia. Hypertonic saline was effective in
preventing nephrotoxicity. Ondansetron was a very effective antiemetic in the first weeks of treatment but its
efficacy waned later on. Responses were observed in head and neck cancer, melanoma and mesothelioma. At
the dose level of 80 mg m-2 the optimal dose intensity was reached. This schedule will be tested further in
phase 11 studies.
Cisplatin is one of the most active and most widely used
cytostatics. In vitro studies in human cancer cell lines and
clinical trials in several tumour types have suggested a dose-
response relationship for cisplatin (Pillay et al., 1986; Bruck-
ner et al., 1984; Ozols et al., 1985; Ozols, 1989; Gandara et
al., 1989; Forastiere et al., 1987). The application of high
doses or frequent administration of lower doses of cisplatin is
however, hampered by side effects such as severe nausea and
vomiting, neurotoxicity and nephrotoxicity.
Until recently, even with the use of the most active anti-
emetic combination regimen (metoclopramide with lorazepam
and dexamethasone), a considerable proportion of patients
suffered from nausea and vomiting whereas the new 5HT3-
antagonists are now found to be more effective in preventing
acute nausea and vomiting induced by cisplatin (Cubbedu et
al., 1990; Marty et al., 1990; Smith et al., 1990; de Mulder et
al., 1990).
In addition the risk of cisplatin nephrotoxicity can be
decreased by administering cisplatin in hypertonic saline 3%
(Ozols et al., 1985; Gandara et al., 1989; Forastiere et al.,
1987; Earhart et al., 1983). These protective measures may
theoretically allow a higher cisplatin dose intensity (D.I.). We
therefore performed a phase I/II study with six weekly cycles
of cisplatin, administered in 3% hypertonic saline, combined
with the 5HT3-antagonist ondansetron as antiemetic.
Patients and methods
Patients were required to have metastatic or locally advanced
cancer for which no adequate local treatment was available,
age 18-75 years, a WHO performance status of 2 or better,
an adequate bone marrow function with WBC > 3 1091-'
and platelets > 100 1091-', a serum bilirubin <25 l.mol 1-'
and a creatinine clearance > 60 ml min-'. All patients gave
oral informed consent according to institutional regulations,
had a complete clinical work up including medical history,
physical examination, haematology and biochemistry tests, a
creatinine clearance, chest X-ray, ECG and ultrasound and/
or CT-scans to measure indicator lesions.
The infusion schedule consisted of: pre-hydration with
1000 ml of dextrose-saline over 4 h with 20 mmol KCI +
2 gram MgSO4; cisplatin powder diluted in 250 ml 3% NaCl
and administered over 3 h followed by post-hydration with
2000 ml dextrose-saline with 40 mmol KCI + 4 gram MgSO4
over 8 h. As antiemetic all patients received ondansetron at a
dose of 8 mg i.v. bolus before the start of cisplatin, followed
by mg h-' continuous intravenous infusion for 12 h.
This regimen was repeated weekly for 6 weeks. Treatment
was postponed for 1 week if WBC were <2.5 x I09 1-'
and/or platelets <75 x 109 1'. In case of treatment delay of
> 3 weeks or the occurrence of nephro- or neurotoxicity
> grade 2 the patient was taken off study.
Dose reductions were not allowed. At each dose level at
least three patients were treated and evaluated for toxicity
before patients were entered at the next dose level. All
patients had a weekly physical examination and determina-
tions of haemoglobin, WBC and platelets, serum calcium,
magnesium, creatinine, liver function tests and creatinine
clearance. Response to treatment was evaluated 2 weeks after
the last cisplatin administration. For response evaluation and
toxicity grading, with exception of grading of gastrointestinal
toxicity, the WHO criteria were used (WHO, 1979). Toxicity
is reported as the worst grade observed during the whole
treatment period. For grading of nausea and vomiting a
modified grading system was used: grade 0 none, grade 1:
mild to moderate nausea not interfering with adequate fluid
and food intake, grade 2: nausea interfering with adequate
fluid and/or food intake and/or vomiting <5 x in 24h,
grade 3: any nausea or vomiting worse than grade 2 but not
requiring i.v. support and grade 4 any nausea and/or
vomiting for which hospital admission was necessary.
The dose intensity of cisplatin was calculated as the total
amount of cisplatin administered divided by the total number
of treatment weeks necessary to administer the total dose and
is expressed in milligrams per square meter per week; in
patients completing six treatment cycles in 6 weeks the total
dose is divided by 6; in case of treatment delay the total dose
administered is divided by 6 + the number of weeks delay. In
those patients who did not receive the last dosage(s) due to
toxicity or progressive disease the total amount of cisplatin
administered was calculated over 6 weeks.
Results
Twenty-five patients were entered in the study. The patient
characteristics are given in Table I. Six patients had been
pretreated with a non-cisplatin chemotherapy regimen. The
starting dose of cisplatin was 50 mg m-2 week- '. The number
of patients and the number of administrations per dose level
are shown in Table II. At the dose levels of 50, 60 and
70 mgm-2 toxicity was mild to moderate and uncomplicated
with the exception of one patient at 70 mg m-2 who did not
receive the sixth cycle because of slow recovery of platelets.
The other patients had no treatment delays.
At the dose level of 80 mg m-2 two patients developed
grade 3 myelosuppression, and in one heavily pretreated
patient thrombocytopenia grade 4 occurred. Therefore three
additional patients were entered at this dose level, all
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Table I Patient characteristics
Total number of patients 25
Male:female 18:7
Median (range) years 51 (23-69)
Median performance status (WHO, range) 1 (0-1)
Tumour types
Head/neck cancer locally advanced 9
Head/neck cancer metastatic 3
Mesothelioma pleura 7
Sarcoma 2
Melanoma 2
Adenocarcinoma unknown primary I
Lung squamous cell carcinoma 6
developing grade 3 myelosuppression, mainly occurring after
the fourth cycle. Subsequently the dose was escalated to
85 mg m-2. At this dose thrombocytopenia grade 4 was seen
in four out of seven patients, while leucocytopenia grade 3
developed in two. One of these patients, with obstructive
lung cancer, died due to sepsis and pneumonia with haemo-
ptysis, during leucocytopenia and thrombocytopenia. There-
after three additional chemonaive patients were treated at
80 mg m- without any grade 4 toxicity. At this dose level
two patients received six cycles without any delay, five
patients had one cycle delayed for 1 week and two patients
did not receive the sixth cisplatin dose, one because of slow
recovery of platelets and one because of progressive
disease.
The median time to development for both leucocytopenia
and thrombocytopenia was 35 days. The median duration of
leucocytopenia was 7 and of thrombocytopenia 10 days. All
25 patients in the study developed grade 1 anaemia.
Nephrotoxicity WHO grade 1 was observed in eight
patients, solely at the dose levels of 80 and 85 mg m-2. At the
lower dose levels most patients had a slight increase in serum
creatinine but none exceeded the upper level of WHO grade
0. In five of the eight patients who developed grade 1 nephro-
toxicity the serum creatinine improved to near normal pre-
treatment levels after cessation of treatment. An overview of
the haematologic toxicity and nephrotoxicity in relation to
the cisplatin dose level is given in Table III. Other toxicities
are shown in Table IV. Asymptomatic hypomagnesemia
<0.65 mmol 1' was observed in three patients, one each at
dose levels of 50, 70 and 75 mg m-2 in all occurring after the
4th cisplatin administration. Six patients at the two highest
dose levels experienced neurotoxicity grade 1. In one patient
the neurotoxicity deteriorated to grade 2 after completion of
treatment, but this patient also had a vitamin B12 deficiency.
In the other patients no late deterioration of neurotoxicity or
late development of neurotoxicity was observed. Ototoxicity
grade 2 (tinnitus) was observed in one patient at 70 mg m-2
and grade 3 (hearing loss requiring a hearing aid) in two
patients at 85mgm2.
Ondansetron was highly effective in preventing nausea and
vomiting, especially in the first 3-4 weeks of treatment.
However, at the dose level of 85 mg m-2 three out of seven
patients vomited during the first administrations. The effect
of ondansetron waned with the last two to three doses of
cisplatin and, at all dose levels, most patients suffered from
nausea and occasional vomiting during the final weeks of
treatment. Diarrhoea was not observed. Table II also shows
the mean cumulative dose and achieved dose intensity of
cisplatin in mg m2 week-'. At the dose level of 80 mg
m-2week-' the same dose intensity was reached as with the
dose level of 85 mgm-2week-' but with less toxicity.
Twenty-four patients were evaluable for response. We
observed a histologically confirmed complete response in one
patient with malignant melanoma, a partial response in eight
out of nine patients with locally advanced head and neck
cancer and in two out of three patients with local recurrence
and metastatic head and neck cancer. A partial response was
observed in four out of seven patients with mesothelioma.
Most patients with head- and neck cancer were subsequently
irradiated for which reason the duration of response cannot
be determined. In the mesothelioma patients responses lasted
2, 4, and 8 months respectively, while the melanoma patient
is still in complete remission after 30 months.
Discussion
Cisplatin has a broad range of activity in solid tumours and
is widely used in combination chemotherapy regimens. A
relationship between treatment intensity and response has
been shown in ovarian cancer (Ozols et al., 1985; Levin et al.,
1987; Kaye, 1992) but is controversial in other tumour types.
An improvement in treatment outcome with higher than
standard cisplatin doses per course was reported for non
small cell lung cancer (Gralla et al., 1981; Gandara, 1989),
testicular cancer (Samson et al., 1984; Ozols et al., 1988) and
head and neck cancer (Forastiere et al., 1987), but ran-
domised studies comparing standard with high cisplatin
dosages (in general in day 1-5 or day 1 + 8 schedules) failed
to show any benefit for the high dose arms in testicular
cancer (Nichols et al., 1991), non small cell lung cancer
(Einhorn et al., 1986) and malignant melanoma (Mortimer et
al., 1991). Another approach to increase the platinum dose
intensity is to increase the frequency of cisplatin administra-
tion, or to combine cisplatin with its analogue carbo-
platin.
More frequent administration of cisplatin theoretically has
the additional advantage that sublethally damaged tumour
cells may be killed by the next dosage. Suggestive evidence to
support this notion is provided by observations in poor risk
germ cell tumours, where closely spaced cisplatin therapy has
been investigated (Ozols et al., 1988; Horwich et al., 1989;
Lewis et al., 1991). Early studies with weekly administration
of cisplatin were hampered by the side effects which can
nowadays be partly prevented (Corder et al., 1977; Randolph
et al., 1978). We investigated the feasibility of weekly
administration of cisplatin, with administration in 3% hyper-
tonic saline and the concomittant use of ondansetron as
preventive measures.
The starting dose was 50mgm2week' for 6 weeks. At
the dose level of 85 mg m-2 week-' the dose limiting toxicity
was thrombocytopenia and necessitated dosage delays in
most patients jeopardising the dose intensity aimed for. The
dose level of 80 mg m-2 appeared to be safe for previously
untreated patients and allowed a treatment with a mean dose
intensity of 70 mgm2 week-'. The severity of leucocyto-
penia did not differ between the two highest dose levels and
Table II Mean cumulative cisplatin dose and cisplatin dose-intensity achieved
Mean cumulative Mean cisplatin % Cisplatin
Cisplatin dose No. patientsl dose of cisplatin dose intensity delivered of
Dose level (mg m-2wk-') no. administr. given (mgm-2) (mg m-2 wk-') planned dose
1 50 3/18 300 50 100
2 60 3/18 360 60 100
3 70 3/17a 397 66 94
4 80 9/52b 462 70 87.5
5 85 7/40c 485 70 70
aOne patient did not receive 6th cisplatin dose because of progressive disease. bTwo patients did not receive
6th cisplatin dose because of slow recovery of platelets or progressive disease. cOne patient received only four
courses of cisplatin because of infectious complication.CISPLATIN FOR ADVANCED SOLID TUMOURS 791
Table III Haematologic and nephrotoxicity observed
Median serum Highest serum
Median nadir x 10 1-' creatinine at start creatinine observed
Dose Cisplatin dose No. patients! Platelets WBC of treatment during treatment
level (mgm-2wk-') no. administr. (range) (range) (+range; jumoll-') (+range; pmoll-')
1 50 3/18 95 2-4 83 104
(46-221) (1.8-5.5) (80-93) (93-106)
2 60 3/18 158 3.2 78 91
(64-223) (2.1-5.2) (70-128) (77-132)
3 70 3/17a 87 3.6 92 104
(42-92) (2.3-3.9) (91-103) (102-114)
4 80 9/52 58b 2.5 99 114
(25-181) (1.6-4.7) (67-121) (76-180)
5 85 7/40 27c 3.0 82 156
(14-186) (1.2-3.6) (69-95) (76-183)
aOne patient did not receive 6th cisplatin dose because of progressive disease. bOne patient grade 4. cFour
patients grade 4; toxic death.
Table IV Other toxicities observed (WHO; worst grade
observed)
CDDP dose in No.
mg m 2 wk-i patients GP Neuro Oto
WHO Grade
01234 01234 01234
50 3 02100 30000 30000
60 3 10200 30000 30000
70 3 00210 30000 20100
80 9 11520 44100 90000
85 7 10330 61000 50020
aModified criteria; see Patients and methods.
grade 4 leucocytopenia was not observed (Table III). The
risk of nephrotoxicity with this schedule is low as is the risk
of neurotoxicity. The risk of ototoxicity, however, is higher
than with standard cisplatin schedules and is in this study
comparable to other dose intense cisplatin regimens. Nausea
and vomiting could be effectively prevented by ondansetron
in the first 3-4 weeks of treatment especially at dosages
lower than 80 mg m-2. However, with continuation of treat-
ment the efficacy of ondansetron gradually waned. Never-
theless we conclude that weekly administration of cisplatin
for a period of 6 weeks is feasible and when administered in
hypertonic saline and combined with a 5-HT3 antagonist a
higher dose intensity can be reached than with previously
reported weekly schedules or with schedules combining cis-
platin and carboplatin. Higano et al. (1991) also administered
cisplatin on a weekly schedule in non small cell lung cancer
but failed to reach a high response rate; in this study weekly
cisplatin was combined with mitomycin C, vinblastin and
fluorouracil which hampered the cisplatin dose intensity
reached which was approximately 40-44mgm2weekl'.
Studies with the combination of cisplatin and carboplatin
also appear to have resulted in dose intensities lower than we
achieved with single agent cisplatin (Calvert, 1991). Assuming
a 'normal' surface area of 1.7mg2 and a GFR of 100mg
min-' Calvert (1991) calculated an AUC of 1 unit of carbo-
platin per week to be equivalent in dose intensity to
18.4 mgm-2 of cisplatin per week. Using this formula the
cisplatin equivalent dose intensities varied in the cisplatin
plus carboplatin studies from 36-63 mg m-2 week'-l (Trump
et al., 1987; Kreisman et al., 1990; Dimery et al., 1991; Gill et
al., 1991; Sessa et al., 1991), with the highest dose intensity
only achieved during the first treatment cycle (Hardy et al.,
1991). These dose intensities compare unfavourable with the
dose intensity that we achieved for the whole treatment
period of six cycles. The highest dose intensity reached in
5-day regimens every 4 weeks is 50 mgm-2 week-' (Ozols,
1989) again lower than we achieved. The encouraging results
we observed in head and neck cancer and mesothelioma
warrant further exploration in phase II studies. The dosage
for these studies is 80mgm2 week-' for 6 weeks in
previously untreated patients. However, it is obvious that
randomised studies comparing these new schedules with stan-
dard schedules of cisplatin administration are required to
establish the clinical benefit.
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